Clinical Trials Browser

Phase 2 × Completed × lenvatinib × Clear all

NCT06036836 2026-03-19

MK-4280A-010

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04710628 2026-02-19

PECATI

Phase 2 Completed

Thymoma

NCT05254847 2026-01-20

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms

NCT06138496 2026-01-05

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Phase 2 Completed

Carcinoma, Renal Cell

NCT05532319 2025-12-30

FRONT-1

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03290079 2025-12-22

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Phase 2 Completed

20 enrolled 12 charts

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04428151 2025-12-04

LEAP-009

Phase 2 Completed

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT04704219 2025-12-03

KEYNOTE-B61

Phase 2 Completed

160 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03797326 2025-11-17

LEAP-005

Phase 2 Completed

611 enrolled 27 charts

BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04447755 2025-10-03

E7080-G000-231

Phase 2 Completed

127 enrolled 29 charts

Recurrence

NCT02973997 2025-08-29

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Phase 2 Completed

57 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT05014828 2025-08-24

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors

Phase 2 Completed

58 enrolled 16 charts

Other solid neoplasm

Advanced Solid Tumor

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02678780 2025-07-24

TALENT

Phase 2 Completed

123 enrolled 37 charts

Neuroendocrine Tumors

NCT04924101 2025-07-23

KEYNOTE-B99

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT05101629 2025-07-23

Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT03516981 2025-07-01

MK-3475-495

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03609359 2025-04-16

Lenva+Pembro

Phase 2 Completed

29 enrolled 20 charts

Gastrointestinal

Stomach Neoplasms

NCT03173560 2025-04-01

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Phase 2 Completed

343 enrolled 25 charts

Carcinoma, Renal Cell

NCT04401800 2025-03-10

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Phase 2 Completed

64 enrolled 23 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT05010668 2025-02-21

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Phase 2 Completed

Gastrointestinal

Cholangiocarcinoma

NCT04361331 2025-02-07

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Phase 2 Completed

Gastrointestinal

Cholangiocarcinoma

NCT03477175 2025-01-07

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Phase 2 Completed

40 enrolled 13 charts

Other solid neoplasm

Solid Tumors

NCT05003700 2024-11-05

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT05485896 2024-09-19

Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC

Phase 2 Completed

Carcinoma, Renal Cell

NCT04154189 2024-07-22

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

Phase 2 Completed

81 enrolled 22 charts

Recurrence, Osteosarcoma

NCT04193553 2024-06-18

LENVAGIST

Phase 2 Completed

Neoplasm Metastasis

NCT02640508 2024-05-09

Eribulin and Lenvatinib in Advanced Solid Tumors

Phase 2 Completed

29 enrolled 13 charts

Neoplasms

NCT03321630 2024-03-27

A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies

Phase 2 Completed

24 enrolled 10 charts

Gastrointestinal

Stomach Neoplasms

NCT03008369 2024-02-20

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

Phase 2 Completed

3 enrolled 9 charts

Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT01111461 2023-06-22

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

Phase 2 Completed

133 enrolled 16 charts

Endometrial Neoplasms

NCT04044313 2023-06-12

HAIC Plus Lenvatinib and Toripalimab for Advanced HCC

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT03841201 2023-05-12

Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT03895970 2023-03-29

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

Phase 2 Completed

Gastrointestinal

Cholangiocarcinoma

NCT02915783 2023-01-17

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

Phase 2 Completed

41 enrolled 11 charts

Neoplasm Metastasis

NCT01137604 2022-09-29

A Study in Subjects With Recurrent Malignant Glioma

Phase 2 Completed

151 enrolled 17 charts

Glioma

NCT02702388 2021-11-24

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

Phase 2 Completed

241 enrolled 32 charts

Thyroid Neoplasms

NCT04656249 2021-06-04

LENABC

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT02579616 2020-12-23

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

Phase 2 Completed

29 enrolled 16 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT01728623 2020-08-14

A Study of E7080 in Subjects With Advanced Thyroid Cancer

Phase 2 Completed

51 enrolled 15 charts

Thyroid Neoplasms

NCT02726503 2020-06-17

HOPE

Phase 2 Completed

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT00784303 2020-04-22

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Phase 2 Completed

117 enrolled 19 charts

Thyroid Neoplasms

NCT01136967 2019-11-13

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Phase 2 Completed

182 enrolled 63 charts

Melanoma

NCT01877083 2019-08-13

Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

Phase 2 Completed

25 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01529112 2017-09-26

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Phase 2 Completed

135 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung